One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial

Cardiovascular Intervention and Therapeutics

Volumn 31, Issue 3, 2016, Pages 196-209

  Natsuaki, Masahiro ^a   Morimoto, Takeshi ^b   Yamamoto, Erika ^c   Shiomi, Hiroki ^c   Furukawa, Yutaka ^d   Abe, Mitsuru ^e   Nakao, Koichi ^f   Ishikawa, Tetsuya ^g   Kawai, Kazuya ^h   Yunoki, Kei ⁱ   Shimizu, Shogo ^j   Akao, Masaharu ^e   Miki, Shinji ^k   Yamamoto, Masashi ^l   Okada, Hisayuki ^m   Hoshino, Kozo ⁿ   Kadota, Kazushige ^o   Morino, Yoshihiro ^p   Igarashi, Keiichi ^q   Tanabe, Kengo ^r   Kozuma, Ken ^s   Kimura, Takeshi ^c   more..

^a SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^f SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^g Division of Pathology   (Japan)

^h Chikamori Hospital   (Japan)

ⁱ OSAKA CITY GENERAL HOSPITAL   (Japan)

^j Mashiko Hospital   (Japan)

^k MITSUBISHI KYOTO HOSPITAL   (Japan)

^l KIMITSU CHUO HOSPITAL   (Japan)

^m SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

ⁿ Nagai Hospital   (Japan)

^o KURASHIKI CENTRAL HOSPITAL   (Japan)

^p IWATE MEDICAL UNIVERSITY   (Japan)

^q Hokkaido Social Insurance Hospital   (Japan)

^r MITSUI MEMORIAL HOSPITAL   (Japan)

^s TEIKYO UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

Coronary artery disease; Coronary stent; Dual antiplatelet therapy; Everolimus eluting stent

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; ANTITHROMBOCYTIC AGENT; CHROMIUM DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; COBALT CHROMIUM EVEROLIMUS ELUTING STENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DRUG ELUTING STENT; DRUG WITHDRAWAL; DUAL ANTIPLATELET THERAPY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SIDE EFFECT; STENT THROMBOSIS; TREATMENT OUTCOME; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CORONARY ARTERY DISEASE; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR;

AGED; CHROMIUM ALLOYS; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 84976601241     PISSN: 18684300     EISSN: 18684297     Source Type: Journal    
DOI: 10.1007/s12928-015-0366-9     Document Type: Article

References (21)

1. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of Xience/Promus versus Cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125:505–13.
2. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125:2015–26.
3. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60:1340–8.
4. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310:2510–22.
5. Stefanini GG, Siontis GC, Cao D, Heg D, Juni P, Windecker S. Short versus long duration of DAPT after DES implantation: a meta-analysis. J Am Coll Cardiol. 2014;64:953–4.
6. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;2014(35):2541–619.
7. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D’Ascenzo F, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379:1393–402.
8. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: A report of the American College of Cardiology foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation. 2011;124:2574–609.
9. Kimura T, Morimoto T, Natsuaki M, Shiomi H, Igarashi K, Kadota K, et al. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the randomized evaluation of sirolimus-eluting versus everolimus-eluting stent trial (RESET). Circulation. 2012;126:1225–36.
10. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation. 2009;119:987–95.
11. Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020–9.
12. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: Clinical findings through hospital discharge. Circulation. 1987;76:142–54.
13. Simoons ML, et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993;329:673–82.
14. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. Euro Inter. 2005;1:219–27.
15. Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64:2086–97.
16. Gilard M, Barragan P, Noryani AA, Noor HA, Majwal T, Hovasse T, et al. Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial. J Am Coll Cardiol. 2015;65:777–86.
17. Schulz-Schupke S, Byrne RA, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015;36:1252–63.
18. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123:1400–9.
19. Tada T, Byrne RA, Simunovic I, King LA, Cassese S, Joner M, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Inter. 2013;6:1267–74.
20. Raber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation. 2012;125:1110–21.
21. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155–66.